0001567619-20-018008.txt : 20201020
0001567619-20-018008.hdr.sgml : 20201020
20201020165822
ACCESSION NUMBER: 0001567619-20-018008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201020
FILED AS OF DATE: 20201020
DATE AS OF CHANGE: 20201020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Versant Venture Capital VI, L.P.
CENTRAL INDEX KEY: 0001687880
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 201248793
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: (415) 801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Versant Vantage I, L.P.
CENTRAL INDEX KEY: 0001765253
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 201248794
BUSINESS ADDRESS:
STREET 1: ONE SANSOME, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: (415) 801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
FORMER NAME:
FORMER CONFORMED NAME: Versant Opportunity Fund I, L.P.
DATE OF NAME CHANGE: 20190117
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2020-10-20
1
0001799448
Aligos Therapeutics, Inc.
ALGS
0001687880
Versant Venture Capital VI, L.P.
ONE SANSOME STREET, SUITE 3630
SAN FRANCISCO
CA
94104
0
0
1
0
0001765253
Versant Vantage I, L.P.
ONE SANSOME STREET, SUITE 3630
SAN FRANCISCO
CA
94104
0
0
1
0
Common Stock
2020-10-20
4
C
0
2145991
A
2145991
D
Common Stock
2020-10-20
4
C
0
198839
A
2344830
D
Common Stock
2020-10-20
4
C
0
85065
A
2429895
D
Common Stock
2020-10-20
4
C
0
463959
A
463959
I
See footnote
Common Stock
2020-10-20
4
C
0
198485
A
662444
I
See footnote
Common Stock
2020-10-20
4
P
0
200000
15
A
862444
I
See footnote
Series A Preferred Stock
2020-10-20
4
C
0
2145991
0.00
D
Common Stock
2145991
0
D
Series B-1 Preferred Stock
2020-10-20
4
C
0
198839
0.00
D
Common Stock
198839
0
D
Series B-1 Preferred Stock
2020-10-20
4
C
0
463959
0.00
D
Common Stock
463959
0
I
See footnote
Series B-2 Preferred Stock
2020-10-20
4
C
0
85065
0.00
D
Common Stock
85065
0
D
Series B-2 Preferred Stock
2020-10-20
4
C
0
198485
0.00
D
Common Stock
198485
0
I
See footnote
Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Thomas Woiwode Ph.D. is a managing director of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the Issuer.
These securities are held of record by by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Thomas Woiwode Ph.D. is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I and disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer.
/s/ Versant Venture Capital VI, L.P.
By: Versant Ventures VI GP, L.P. Its: General Partner
By: Versant Ventures VI GP-GP, LLC
By: Robin L. Praeger Its: Managing Director
/s/ Versant Vantage I, LP
By: Versant Vantage I GP, L.P. Its: General Partner
By: Versant Vantage I GP-GP, LLC Its: General Partner
By: Robin L. Praeger Its: Managing Director
See Remarks
2020-10-20